Trident Lifeline Ltd (TLL) — shareholding pattern, promoter holding, financials and share price
About Trident Lifeline Ltd (TLL)
Trident Lifeline Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as TLL and on the BSE under scrip code 543616. Its ISIN is INE0MKA01014.
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals products [1]
Trident Lifeline Limited is a rapidly growing pharmaceutical company, specializing in manufacturing and exporting pharmaceutical formulations globally. It operates in several regions, including Africa, Latin America, and Asia.
The company has shown robust financial growth, with a 44% year-over-year revenue increase in Q3FY26. Its EBITDA also surged by 53% in the same period, demonstrating a strong operational performance.
Listed peers in Pharmaceuticals: Medicamen Biotech Ltd, Medico Remedies Ltd, Infinium Pharmachem Ltd, Everest Organics Ltd, BDH Industries Ltd, Astonea Labs Ltd.
Valuation & Returns
10 Jul 2026At ₹262.5 a share on 10 Jul 2026, Trident Lifeline Ltd (TLL) was valued at a price-to-earnings ratio of 16.79x against an industry P/E of 36.41x and a price-to-book of 4.86x on a book value of ₹54.02 per share as of Mar 2025. Solomo computes return on equity of 28.95% and return on capital employed of 23.29% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Dec 2025.
- P/E
- 16.79x
- Industry P/E
- 36.41x
- P/B
- 4.86x
- EPS (TTM)
- ₹15.64
- Book value / share
- ₹54.02
- ROE
- 28.95%
- ROCE
- 23.29%
- ROA
- 11.96%
- Debt / equity
- 0.84x
- Dividend yield
- 0%
- EBITDA margin
- 28.97%
- 52-week range
- ₹229.95 – ₹328
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Trident Lifeline Ltd (TLL) reported revenue of ₹129 crore, net profit of ₹19 crore and earnings per share of ₹15.96. That compares with revenue of ₹87 crore and net profit of ₹10 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹76 crore and net profit ₹11 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 22 | 32 | 45 | 87 | 129 |
| Net profit (₹ cr) | 4 | 6 | 6 | 10 | 19 |
| EPS (₹) | 4.94 | 5.24 | 5.51 | 10.22 | 15.96 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 68.88% | 46.04% | 94.85% |
| Profit growth | - | 48.97% | 76.60% |
| Stock price CAGR | - | 20% | -3% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 62.59% of Trident Lifeline Ltd (TLL) (down 0.26 pp QoQ), foreign institutional investors (FII) hold 5.25% and domestic institutional investors (DII) hold 0.26%. Promoters have pledged 6.9% of their holding. Market capitalisation was ₹313 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2022.
Largest disclosed public shareholders in Jun 2026: Goenka Business And Finance Limited 3.03%, Nav Capital Vcc - Nav Capital Emerging Star Fund 2.63%, HUF 2.32%, Craft Emerging Market Fund Pcc- Elite Capital Fund 1.69%, Chetan Muktilal Mehta Huf 1.01%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 62.59% | 6.9% | 5.25% | 0.26% | 37.41% |
| Mar 2026 | 62.85% | 6.9% | 7.24% | 0.27% | 37.15% |
| Dec 2025 | 64.11% | 6.8% | 7.04% | 0.35% | 35.89% |
| Sep 2025 | 63.11% | 3.4% | 7.71% | 0.41% | 36.89% |
| Jun 2025 | 63.04% | 3.5% | 7.21% | 0.39% | 36.96% |
| Mar 2025 | 63.04% | 3.5% | 6.62% | 0.09% | 36.96% |
| Dec 2024 | 62.99% | 3.5% | 6.09% | - | 37.01% |
| Sep 2024 | 62.99% | - | 6.09% | - | 37.01% |